(19)
(11) EP 4 770 639 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24762659.1

(22) Date of filing: 28.08.2024
(51) International Patent Classification (IPC): 
A61K 31/40(2006.01)
A61P 3/00(2006.01)
A61P 3/10(2006.01)
A61P 25/28(2006.01)
 A61K 45/00(2006.01)
A61P 3/04(2006.01)
A61P 25/24(2006.01)
A61P 29/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/40; A61K 45/00; A61P 3/00; A61P 3/04; A61P 3/10; A61P 25/24; A61P 29/00; A61P 25/28
(86) International application number:
PCT/EP2024/074056
(87) International publication number:
WO 2025/045932 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 28.08.2023 US 202363579218 P

(71) Applicant: Noema Pharma AG
4051 Basel (CH)

(72) Inventor:
  • GARIBALDI, George
    4052 Basel (CH)

(74) Representative: Icosa 
83 avenue Denfert-Rochereau
75014 Paris
75014 Paris (FR)

   


(54) A TRIPLE REUPTAKE INHIBITOR FOR USE IN METHODS OF TREATING A BEHAVIORAL IMMUNO-METABOLIC CLUSTER CONDITION OR DISORDER